These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 31056260)
21. Lico A Enhances Nrf2-Mediated Defense Mechanisms against t-BHP-Induced Oxidative Stress and Cell Death via Akt and ERK Activation in RAW 264.7 Cells. Lv H; Ren H; Wang L; Chen W; Ci X Oxid Med Cell Longev; 2015; 2015():709845. PubMed ID: 26576227 [TBL] [Abstract][Full Text] [Related]
22. Sulforaphane Attenuates H₂O₂-induced Oxidant Stress in Human Trabecular Meshwork Cells (HTMCs) via the Phosphatidylinositol 3-Kinase (PI3K)/Serine/Threonine Kinase (Akt)-Mediated Factor-E2-Related Factor 2 (Nrf2) Signaling Activation. Liu Y; Liu P; Wang Q; Sun F; Liu F Med Sci Monit; 2019 Jan; 25():811-818. PubMed ID: 30689624 [TBL] [Abstract][Full Text] [Related]
23. Osthole Protects Bone Marrow-Derived Neural Stem Cells from Oxidative Damage through PI3K/Akt-1 Pathway. Yan YH; Li SH; Li HY; Lin Y; Yang JX Neurochem Res; 2017 Feb; 42(2):398-405. PubMed ID: 27734182 [TBL] [Abstract][Full Text] [Related]
24. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823 [TBL] [Abstract][Full Text] [Related]
26. Piracetam mitigates nephrotoxicity induced by cisplatin via the AMPK-mediated PI3K/Akt and MAPK/JNK/ERK signaling pathways. El-Dessouki AM; Alzokaky AA; Raslan NA; Ibrahim S; Salama LA; Yousef EH Int Immunopharmacol; 2024 Aug; 137():112511. PubMed ID: 38909496 [TBL] [Abstract][Full Text] [Related]
27. Cyanidin-3-O-glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells. Li X; Zhao J; Yan T; Mu J; Lin Y; Chen J; Deng H; Meng X J Food Sci; 2021 Jun; 86(6):2700-2712. PubMed ID: 33908630 [TBL] [Abstract][Full Text] [Related]
28. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456 [TBL] [Abstract][Full Text] [Related]
29. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Gao AM; Ke ZP; Wang JN; Yang JY; Chen SY; Chen H Carcinogenesis; 2013 Aug; 34(8):1806-14. PubMed ID: 23563091 [TBL] [Abstract][Full Text] [Related]
30. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Lee S; Choi EJ; Jin C; Kim DH Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433 [TBL] [Abstract][Full Text] [Related]
31. Baicalein enhances cisplatin sensitivity in cervical cancer cells by promoting cuproptosis through the Akt pathway. Jin Y; Wu Q; Pan S; Zhou Q; Liu H; Zhang Q; Zhang J; Zhu X Biomed Pharmacother; 2024 Oct; 179():117415. PubMed ID: 39265236 [TBL] [Abstract][Full Text] [Related]
32. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985 [TBL] [Abstract][Full Text] [Related]
33. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350 [TBL] [Abstract][Full Text] [Related]
34. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Roh JL; Kim EH; Jang H; Shin D Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440 [TBL] [Abstract][Full Text] [Related]
35. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway. Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458 [TBL] [Abstract][Full Text] [Related]
37. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Syu JP; Chi JT; Kung HN Oncotarget; 2016 Mar; 7(12):14659-72. PubMed ID: 26894974 [TBL] [Abstract][Full Text] [Related]
38. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Chian S; Li YY; Wang XJ; Tang XW Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924 [TBL] [Abstract][Full Text] [Related]
39. MTA1 overexpression induces cisplatin resistance in nasopharyngeal carcinoma by promoting cancer stem cells properties. Feng X; Zhang Q; Xia S; Xia B; Zhang Y; Deng X; Su W; Huang J Mol Cells; 2014 Sep; 37(9):699-704. PubMed ID: 25245523 [TBL] [Abstract][Full Text] [Related]
40. [Osthole ameliorates glutamate-induced toxicity in HT22 cells via activating PI3K/Akt signaling pathway]. Mao X; Wang Z; Zhou H; Liu Z; Zhou Y Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):955-9. PubMed ID: 26408613 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]